MRI in ocular drug delivery

NMR in Biomedicine

Volumn 21, Issue 9, 2008, Pages 941-956

  Li, S Kevin ^a   Lizak, Martin J ^b   Jeong, Eun Kee ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Contrast agent; Drug delivery; Eye; MRI; Ocular

Indexed keywords

CONTRAST AGENT; CONTRAST AGENTS; CURRENT STATUSES; DELIVERY METHODS; DELIVERY SYSTEMS; DEVICE TESTING; EYE; INTRAVITREAL INJECTIONS; MR CONTRAST AGENTS; MRI; NEW OPPORTUNITIES; OCULAR; OCULAR DRUG DELIVERIES; PHARMACEUTICAL RESEARCHES; PHARMACOKINETIC STUDIES;

AGENTS; DRUG THERAPY; ELECTROPHORESIS; ELECTROTHERAPEUTICS; MEDICAL IMAGING; PHARMACOKINETICS;

DRUG DELIVERY;

ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE SODIUM PHOSPHATE; EYE DROPS; FERUMOXSIL; FERUMOXYTOL; FLUORINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; LIPOSOME; MANGANESE; MICROSPHERE; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PEGAPTANIB; PILOCARPINE; POLYMER; RANIBIZUMAB; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNINDEXED DRUG; VASCULOTROPIN; CONTRAST MEDIUM; DRUG;

CONTRAST ENHANCEMENT; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG IMPLANT; EMULSION; EYE DISEASE; FLUORINE NUCLEAR MAGNETIC RESONANCE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; IONTOPHORESIS; MICELLE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; RETINA MACULA EDEMA; RETINITIS; REVIEW; SIGNAL NOISE RATIO; SUSPENSION; SUSTAINED RELEASE PREPARATION; UVEITIS; VITREORETINOPATHY; ANIMAL; EYE; HISTOLOGY; METABOLISM; METHODOLOGY;

ANIMALS; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; EYE; EYE DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; PHARMACEUTICAL PREPARATIONS;

EID: 52349088993     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1230     Document Type: Review

References (112)

1. Bauer NJ, Motamedi M, Wicksted JP, March WF, Webers CA, Hendrikse F. Non-invasive assessment of ocular pharmacokinetics using Confocal Raman Spectroscopy. J. Ocul. Pharmacol. Ther. 1999; 15: 123-134.
2. Szymanski-Exner A, Stowe NT, Salem K, Lazebnik R, Haaga JR, Wilson DL, Gao J. Noninvasive monitoring of local drug release using X-ray computed tomography: optimization and in vitro/in vivo validation. J. Pharm. Sci. 2003; 92: 289-296.
3. Mader K, Bacic G, Domb A, Elmalak O, Langer R, Swartz HM. Noninvasive in vivo monitoring of drug release and polymer erosion from biodegradable polymers by EPR spectroscopy and NMR imaging. J. Pharm. Sci. 1997; 86: 126-134.
4. Massoud TF, Paulmurugan R, De A, Ray P, Gambhir SS. Reporter gene imaging of protein-protein interactions in living subjects. Curr. Opin. Biotechnol. 2007; 18: 31-37.
5. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2003; 2: 123-131.
6. Yang DJ, Kim EE, Inoue T. Targeted molecular imaging in oncology. Ann. Nucl. Med. 2006; 20: 1-11.
7. Richardson JC, Bowtell RW, Mader K, Melia CD. Pharmaceutical applications of magnetic resonance imaging (MRI). Adv. Drug Deliv. Rev. 2005; 57: 1191-1209.
8. Rudin M, Beckmann N, Porszasz R, Reese T, Bochelen D, Sauter A. In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives. NMR Biomed. 1999; 12: 69-97.
9. Beckmann N, Mueggler T, Allegrini PR, Laurent D, Rudin M. From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research. Anat. Rec. 2001; 265: 85-100.
10. Wilson CG. In-vivo monitoring of dosage forms. J. Pharm. Pharmacol. 1998; 50: 383-386.
11. Marciani L, Wickham MS, Bush D, Faulks R, Wright J, Fillery-Travis AJ, Spiller RC, Gowland PA. Magnetic resonance imaging of the behaviour of oil-in-water emulsions in the gastric lumen of man. Br. J. Nutr. 2006; 95: 331-339.
12. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn. Reson. Med. 2004; 51: 1153-1162.
13. Port RE, Schuster C, Port CR, Bachert P. Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging. Cancer Chemother Pharmacol. 2006; 58: 607-617.
14. Chen HH, Le Visage C, Qiu B, Du X, Ouwerkerk R, Leong KW, Yang X. MR imaging of biodegradable polymeric microparticles: a potential method of monitoring local drug delivery. Magn. Reson. Med. 2005; 53: 614-620.
15. Wang Y, Ye F, Jeong EK, Sun Y, Parker DL, Lu ZR. Noninvasive visualization of pharmacokinetics, biodistribution and tumor targeting of poly [N-(2-hydroxypropyl)methacrylamide] in mice using contrast enhanced MRI. Pharm. Res. 2007; 24: 1208-1216.
16. Ye F, Ke T, Jeong EK, Wang X, Sun Y, Johnson M, Lu ZR. Noninvasive visualization of in vivo drug delivery of poly(L-glutamic acid) using contrast-enhanced MRI. Mol. Pharm. 2006; 3: 507-515.
17. Kayyem JF, Kumar RM, Fraser SE, Meade TJ. Receptor-targeted co-transport of DNA and magnetic resonance contrast agents. Chem. Biol. 1995; 2: 615-620.
18. Chowning SL, Susil RC, Krieger A, Fichtinger G, Whitcomb LL, Atalar E. A preliminary analysis and model of prostate injection distributions. Prostate 2006; 66: 344-357.
19. Christodoulou P, Doxas PG, Papadakis CE, Prassopoulos P, Maris T, Helidonis ES. Transtympanic iontophoresis of gadopentetate dimeglumine: preliminary results. Otolaryngol. Head Neck Surg. 2003; 129: 408-413.
20. Maris TG, Prassopoulos P, Papanikolaou N, Christodoulou P, Doxas PG, Helidonis ES, Gourtsoyiannis N. Transtympanic iontophoresis with a biocompatible paramagnetic solution at MR imaging: experimental feasibility study in rabbits. Radiology 2002; 223: 689-694.
21. Barnhart KT, Pretorius ES, Timbers K, Shera D, Shabbout M, Malamud D. In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception 2004; 70: 498-505.
22. Schoenwald R. In Textbook of Ocular Pharmacology, Zimmerman T, Kooner K, Sharir M, Fechtner R (eds). Lippincott-Raven: Philadelphia, 1997.
23. Worakul N, Robinson J. Ocular pharmacokinetics/pharmacodynamics. Eur. J. Pharm. Biopharm. 1997; 44: 71-83.
24. Cekic O, Batman C, Yasar U, Basci NE, Bozkurt A, Kayaalp SO. Comparison of aqueous humour and vitreous humour levels of two 0.3% ciprofloxacin eyedrops. Can. J. Ophthalmol. 1998; 33: 373-376.
25. Sakamoto H, Sakamoto M, Hata Y, Kubota T, Ishibashi T. Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. Eur. J. Ophthalmol. 2007; 17: 372-376.
26. Weijtens O, Feron EJ, Schoemaker RC, Cohen AF, Lentjes EG, Romijn FP, van Meurs JC. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am. J. Ophthalmol. 1999; 128: 192-197.
27. Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 2002; 109: 1887-1891.
28. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin. Drug Deliv. 2006; 3: 275-287.
29. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 2006; 58: 1131-1135.
30. Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin. Exp. Pharmacol Physiol. 2000; 27: 558-562.
31. Mainardes RM, Urban MC, Cinto PO, Khalil NM, Chaud MV, Evangelista RC, Gremiao MP. Colloidal carriers for ophthalmic drug delivery. Curr. Drug Targets 2005; 6: 363-371.
32. Mietz H, Diestelhorst M, Rump AF, Theisohn M, Klaus W, Krieglstein GK. Ocular concentrations of mitomycin C using different delivery devices. Ophthalmologica 1998; 212: 37-42.
33. Taravella MJ, Balentine J, Young DA, Stepp P. Collagen shield delivery of ofloxacin to the human eye. J. Cataract Refract Surg. 1999; 25: 562-565.
34. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. 2001; 52: 37-48.
35. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin. Biol. Ther. 2003; 3: 45-56.
36. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol. Vis. Sci. 2000; 41: 961-964.
37. Olsen TW, Feng X, Wabner K, Conston SR, Sierra DH, Folden DV, Smith ME, Cameron JD. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am. J. Ophthalmol. 2006; 142: 777-787.
38. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin. Drug Deliv. 2004; 1: 99-114.
39. Chang DF, Wong V. Two clinical trials of an intraocular steroid delivery system for cataract surgery. Trans. Am. Ophthalmol. Soc. 1999; 97: 261-274; discussion 274-269.
40. Chang M, Dunn JP. Ganciclovir implant in the treatment of cytomegalovirus retinitis. Expert Rev. Med. Devices 2005; 2: 421-427.
41. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113: 1020-1027.
42. Kodama M, Numaga J, Yoshida A, Kaburaki T, Oshika T, Fujino Y, Wu GS, Rao NA, Kawashima H. Effects of a new dexamethasone- delivery system (Surodex) on experimental intraocular inflammation models. Graefes Arch. Clin. Exp. Ophthalmol. 2003; 241: 927-933.
43. Regillo CD, D'Amico DJ, Mieler WF, Schneebaum C, Beasley CH, Sullins GT. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration. Surv. Ophthalmol. 2007; 52: S70-78.
44. Halhal M, Renard G, Courtois Y, BenEzra D, Behar-Cohen F. Iontophoresis: from the lab to the bed side. Exp. Eye Res. 2004; 78: 751-757.
45. Missel PJ. Finite and infinitesimal representations of the vasculature: ocular drug clearance by vascular and hydraulic effects. Ann. Biomed. Eng. 2002; 30: 1128-1139.
46. Maurice DM. Review: practical issues in intravitreal drug delivery. J. Ocul. Pharmacol. Ther. 2001; 17: 393-401.
47. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 1998; 87: 1479-1488.
48. Ranta VP, Urtti A. Tnansscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv. Drug Deliv. Rev. 2006; 58: 1164-1181.
49. Robinson MR, Lee SS, Kim H, Kim S, Lutz RJ, Galban C, Bungay PM, Yuan P, Wang NS, Kim J, Csaky KG. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp. Eye Res. 2006; 82: 479-487.
50. 1 and T2 mapping using gradient recalled acquisition in the steady state. Magn. Reson. Med. 2003; 49: 515-526.
51. 1 and T2 mapping, using multishot EPI and automated variations of TR and TE at 3T. Joint Annual Meeting ISMRM-ESMRMB 2007, Berlin, Germany. p 1787.
52. Friedrich S, Cheng YL, Saville B. Finite element modeling drug distribution in the vitreous humor of the rabbit eye. Ann. Biomed. Eng. 1997; 25: 303-314.
53. Kim H, Lizak MJ, Tansey G, Csaky KG, Robinson MR, Yuan P, Wang NS, Lutz RJ. Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging. Ann. Biomed. Eng. 2005; 33: 150-164.
54. 19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. Curr. Med. Chem. 2005; 12: 819-848.
55. Campbell GD, Ramaprasad S, Olsen KM, Tryka AF, Komoroski RA, Blaszczak LC, Parr Tr, Jr. Comparison of the in vivo and in vitro nuclear magnetic resonance detection of trifluoromethyl penicillin V in rats. J. Pharm. Sci. 1993; 82: 48-51.
56. Griffiths JR, McIntyre DJ, Howe FA, McSheehy PM. Ojugo ASE, Rodrigues LM, Wadsworth P, Price NM, Lofts F, Nicholson G, Smid K, Noordhuis P, Peters GJ, Stubbs M. Issues of normal tissue toxicity in patient and animal studies: effect of carbogen breathing in rats after 5-fluorouracil treatment. Acta Oncol. 2001; 40: 609-614.
57. 19F NMR imaging of the vascular system in vivo. Magn. Reson. Imaging 1987; 5: 279-285.
58. 19F MRI. Magn. Reson. Imaging 1991; 9: 577-581.
59. 19F MRI: a comparative animal study. Nucl. Med. Biol. 1996; 23: 897-906.
60. Gewiese BK, Noske W, Schilling AM, Stiller DA, Wolf KJ, Foerster MH. Human eye: visualization of perfluorodecalin with F-19 MR imaging. Radiology 1992; 185: 131-133.
61. 19F NMR spectroscopy in the aqueous humour. Exp. Eye Res. 1998; 66: 327-337.
62. 1 of protons in tissue. Invest Radiol. 1984; 19: 76-81.
63. Kang YS, Gore JC, Armitage IM. Studies of factors affecting the design of NMR contrast agents: manganese in blood as a model system. Magn. Reson. Med. 1984; 1: 396-409.
64. Ishimori Y, Yamada K, Kimura H, Fujiwara Y, Yamaguchi I, Monma M, Uematsu H. Correction of inhomogeneous RF field using multiple SPGR signals for high-field spin-echo MRI. Magn. Reson. Med. Sci. 2007; 6: 67-73.
65. Nagy Z, Weiskopf N, Alexander DC, Deichmann R. A method for improving the performance of gradient systems for diffusion-weighted MRI. Magn. Reson. Med. 2007; 58: 763-768.
66. Quesson B, de Zwart JA, Moonen CT. Magnetic resonance temperature imaging for guidance of thermotherapy. J. Magn. Reson. Imaging 2000; 12: 525-533.
67. Crank J. The Mathematics of Diffusion. Oxford University Press: New York, 1980.
68. Lauterbur PC. Image formation by induced local interactions. Examples employing nuclear magnetic resonance. Nature 1973; 242, 5394: 190-191.
69. Bock NA, Silva AC. Manganese: a unique neuron imaging contrast agent. Future Neurol. 2007; 2: 297-305.
70. Kreft BP, Baba Y, Tanimoto A, Finn JP, Stark DD. Orally administered manganese chloride: enhanced detection of hepatic tumors in rats. Radiology 1993; 186: 543-548.
71. 2+-induced contrast. Magn. Reson. Med. 2001; 46: 424-429.
72. Pautler RG, Mongeau R, Jacobs RE. In vivo trans-synaptic tract tracing from the murine striatum and amygdala utilizing manganese enhanced MRI (MEMRI). Magn. Reson. Med. 2003; 50: 33-39.
73. Li SK, Jeong EK, Hastings MS. Magnetic resonance imaging study of current and ion delivery into the eye during transscleral and transcorneal iontophoresis. Invest Ophthalmol. Vis. Sci. 2004; 45: 1224-1231.
74. Dyatlova N, Temkina V, Popov K. Present-day aspects of complex on coordination chemistry. In Complex Formation and Stereochemistry of Coordination Compounds, Buslaev Y (ed). Nova Science: New York, 1996; 1-48.
75. Tweedle MF, Hagan JJ, Kumar K, Mantha S, Chang CA. Reaction of gadolinium chelates with endogenously available ions. Magn. Reson. Imaging 1991; 9: 409-415.
76. Rezai KA, Lappas A, Kohen L, Wiedemann P, Heimann K. Comparison of tight junction permeability for albumin in iris pigment epithelium and retinal pigment epithelium in vitro. Graefes Arch. Clin. Exp. Ophthalmol. 1997; 235: 48-55.
77. Tomita M, Hayashi M, Awazu S. Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells. J. Pharm. Sci. 1996; 85: 608-611.
78. Runge VM, Clanton JA, Herzer WA, Gibbs SJ, Price AC, Partain CL, James AE, Jr. Intravascular contrast agents suitable for magnetic resonance imaging. Radiology 1984; 153: 171-176.
79. Kobayashi H, Brechbiel MW. Dendrimer-based nanosized MRI contrast agents. Curr. Pharm. Biotechnol. 2004; 5: 539-549.
80. Torchilin VP. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv. Drug Deliv. Rev. 2002; 54: 235-252.
81. 3+ protein-chelate conjugates. Magn. Reson. Med. 1986; 3: 541-548.
82. Li Z, Li W, Li X, Pei F, Li Y, Lei H. The gadolinium complexes with polyoxometalates as potential MRI contrast agents. Magn. Reson. Imaging 2007; 25: 412-417.
83. 19F-imaging of albumin at 1.5 T: a potential in-vivo tool. Magn. Reson. Imaging 2001; 19: 839-844.
84. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn. Reson. Med. 2003; 49: 403-408.
85. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004; 17: 484-499.
86. Jung CW Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn. Reson. Imaging 1995; 13: 661-674.
87. Kolodny NH, Freddo TF, Lawrence BA, Suarez C, Bartels SP. Contrast-enhanced magnetic resonance imaging confirmation of an anterior protein pathway in normal rabbit eyes. Invest Ophthalmol. Vis. Sci. 1996; 37: 1602-1607.
88. Cheng HM, Kwong KK, Xiong J, Chang C. GdDTPA-enhanced magnetic resonance imaging of the aqueous flow in the rabbit eye. Magn. Reson. Med. 1991; 17: 237-243.
89. Cheng HM, Kwong KK, Xiong J, Woods BT. Visualization of water movement in the living rabbit eye. Graefes Arch. Clin. Exp. Ophthalmol. 1992; 230: 62-65.
90. Wu JC, Jesmanowicz A, Hyde JS. Anterior segment high resolution MRI: aqueous humor dynamics observed using contrast agents. Exp. Eye Res. 1992; 54: 145-148.
91. Bert RJ, Caruthers SD, Jara H, Krejza J, Melhem ER, Kolodny NH, Patz S, Freddo TF. Demonstration of an anterior diffusional pathway for salutes in the normal human eye with high spatial resolution contrast-enhanced dynamic MR imaging. Invest Ophthalmol. Vis. Sci. 2006; 47: 5153-5162.
92. Freddo TF, Patz S, Arshanskiy Y. Piocarpine's effects on the blood-aqueous barrier of the human eye as assessed by high-resolution, contrast magnetic resonance imaging. Exp. Eye Res. 2006; 82: 458-464.
93. Berkowitz BA, Wilson CA, Tofts PS, Peshock RM. Effect of vitreous fluidity on the measurement of blood-retinal barrier permeability using contrast-enhanced MRI. Magn. Reson. Med. 1994; 31: 61-66.
94. Plehwe WE, McRobbie DW, Lerski RA, Kohner EM. Quantitative magnetic resonance imaging in assessment of the blood-retinal barrier. Invest Ophthalmol. Vis. Sci. 1988; 29: 663-670.
95. Berkowitz BA, Tofts PS, Sen HA, Ando N, de Juan E Jr. Accurate and precise measurement of blood-retinal barrier breakdown using dynamic Gd-DTPA MRI. Invest Ophthalmol. Vis. Sci. 1992; 33: 3500-3506.
96. Sen HA, Berkowitz BA, Ando N, de Juan E Jr. In vivo imaging of breakdown of the inner and outer blood-retinal barriers. Invest Ophthalmol. Vis. Sci. 1992; 33: 3507-3512.
97. Berkowitz BA, Sato Y, Wilson CA, de Juan E. Blood-retinal barrier breakdown investigated by real-time magnetic resonance imaging after gadolinium-diethylenetriaminepentaacetic acid injection. Invest Ophthalmol. Vis. Sci. 1991; 32: 2854-2860.
98. Sato Y, Berkowitz BA, Wilson CA, de Juan E Jr. Blood-retinal barrier breakdown caused by diode vs argon laser endophotocoagulation. Arch. Ophthalmol. 1992; 110: 277-281.
99. Metrikin DC, Wilson CA, Berkowitz BA, Lam MK, Wood GK, Peshock RM. Measurement of blood-retinal barrier breakdown in endotoxin-induced endophthalmitis. Invest Ophthalmol. Vis. Sci. 1995; 36: 1361-1370.
100. Berkowitz BA, Roberts R, Luan H, Peysakhov J, Mao X, Thomas KA. Dynamic contrast-enhanced MRI measurements of passive permeability through blood retinal barrier in diabetic rats. Invest Ophthalmol. Vis. Sci. 2004; 45: 2391-2398.
101. Wilson CA, Berkowitz BA, Funatsu H, Metrikin DC, Harrison DW, Lam MK, Sonkin PL. Blood-retinal barrier breakdown following experimental retinal ischemia and reperfusion. Exp. Eye Res. 1995; 61: 547-557.
102. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch. Ophthalmol. 1992; 110: 1155-1159.
103. Ando N, Sen HA, Berkowitz BA, Wilson CA, de Juan E Jr. Localization and quantitation of blood-retinal barrier breakdown in experimental proliferative vitreoretinopathy. Arch. Ophthalmol. 1994; 112: 117-122.
104. Alikacem N, Yoshizawa T, Nelson KD, Wilson CA. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits. Invest Ophthalmol. Vis. Sci. 2000; 41: 1561-1569.
105. Garner WH, Scheib S, Berkowitz BA, Suzuki M, Wilson CA, Graff G. The effect of partial vitrectomy on blood-ocular barrier function in the rabbit. Curr. Eye Res. 2001; 23: 372-381.
106. Molokhia SA, Jeong EK, Higuchi WI, Li SK. Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imaging. Int. J. Pharm. 2007; 335: 46-53.
107. Molokhia SA, Jeong EK, Higuchi WI, Li SK. Examination of barriers and barrier alteration in transscleral iontophoresis. J. Pharm. Sci. in press.
108. Kim H, Robinson MR, Lizak MJ, Tansey G, Lutz RJ, Yuan P, Wang NS, Csaky KG. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol. Vis. Sci. 2004; 45: 2722-2731.
109. Li SK, Molokhia SA, Jeong EK. Assessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging. Pharm. Res. 2004; 21: 2175-2184.
110. Kim SH, Lutz RJ, Galban CJ, Wang NS, Csaky KG. Analysis of drug elimination kinetics after subconjunctival injection using magnetic resonance imaging. ARVO Annual Meeting 2007. p B322, Program 5785.
111. Jockovich ME, Murray TG, Clifford PD, Moshfeghi AA. Posterior juxtascleral injection of anecortave acetate: magnetic resonance and echographic imaging and localization in rabbit eyes. Retina 2007; 27: 247-252.
112. Kim SH, Galban CJ, Lutz RJ, Dedrick RL, Csaky KG, Lizak MJ, Wang NS, Tansey G, Robinson MR. Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol. Vis. Sci. 2007; 48: 808-814.